Scientific article
Case report
OA Policy
English

Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with CSMD3 mutation

Published in

Gynecologic Oncology Reports, vol. 33, 100600

Publication date

2020

Abstract

•Metastatic CSMD3 mutated HGSOC showed objective and sustained response to pembrolizumab.•The tumor was massively infiltrated by CD8+ T cells while PD-L1 TPS was at 10%.•CSMD3 mutated HGSOC showed up-regulation of CCL5 and CXCL9.

UNIGE research groups

Citation (ISO format)

TERZIC, Julie et al. Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with CSMD3 mutation. In: Gynecologic Oncology Reports, 2020, vol. 33, p. 100600. doi: 10.1016/j.gore.2020.100600

Main files (1)

Article (Published version)

Identifiers

Journal ISSN

2352-5789
299views
265downloads

Technical informations

Creation

22/12/2020 09:17:00

First validation

22/12/2020 09:17:00

Update

13/10/2025 16:40:27

Status update

15/03/2023 23:46:19

Last indexation

25/09/2026 14:39:50
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated